Your browser doesn't support javascript.
loading
Design and methods of the Population Assessment of Tobacco and Health (PATH) Study.
Hyland, Andrew; Ambrose, Bridget K; Conway, Kevin P; Borek, Nicolette; Lambert, Elizabeth; Carusi, Charles; Taylor, Kristie; Crosse, Scott; Fong, Geoffrey T; Cummings, K Michael; Abrams, David; Pierce, John P; Sargent, James; Messer, Karen; Bansal-Travers, Maansi; Niaura, Ray; Vallone, Donna; Hammond, David; Hilmi, Nahla; Kwan, Jonathan; Piesse, Andrea; Kalton, Graham; Lohr, Sharon; Pharris-Ciurej, Nick; Castleman, Victoria; Green, Victoria R; Tessman, Greta; Kaufman, Annette; Lawrence, Charles; van Bemmel, Dana M; Kimmel, Heather L; Blount, Ben; Yang, Ling; O'Brien, Barbara; Tworek, Cindy; Alberding, Derek; Hull, Lynn C; Cheng, Yu-Ching; Maklan, David; Backinger, Cathy L; Compton, Wilson M.
Afiliación
  • Hyland A; Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Ambrose BK; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Conway KP; National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • Borek N; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Lambert E; National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • Carusi C; Westat, Rockville, Maryland, USA.
  • Taylor K; Westat, Rockville, Maryland, USA.
  • Crosse S; Westat, Rockville, Maryland, USA.
  • Fong GT; University of Waterloo, Waterloo, Ontario, USA.
  • Cummings KM; University of Waterloo, Waterloo, Ontario, USA.
  • Abrams D; Medical University of South Carolina, Charleston, South Carolina, USA.
  • Pierce JP; Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, District of Columbia, USA; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Sargent J; University of California at San Diego, San Diego, California, USA.
  • Messer K; Dartmouth College, Hanover, New Hampshire, USA.
  • Bansal-Travers M; University of California at San Diego, San Diego, California, USA.
  • Niaura R; Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Vallone D; Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, District of Columbia, USA; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Hammond D; Schroeder Institute for Tobacco Research and Policy Studies, Truth Initiative, Washington, District of Columbia, USA; The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Hilmi N; Ontario Institute for Cancer Research, Toronto, Ontario, USA.
  • Kwan J; National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • Piesse A; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Kalton G; Westat, Rockville, Maryland, USA.
  • Lohr S; Westat, Rockville, Maryland, USA.
  • Pharris-Ciurej N; Westat, Rockville, Maryland, USA.
  • Castleman V; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Green VR; Westat, Rockville, Maryland, USA.
  • Tessman G; National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • Kaufman A; Kelly Government Solutions, Rockville, Maryland, USA.
  • Lawrence C; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • van Bemmel DM; National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • Kimmel HL; Westat, Rockville, Maryland, USA.
  • Blount B; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Yang L; National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
  • O'Brien B; CDC National Center for Environmental Health, US Department of Health and Human Services, Atlanta, Georgia, USA.
  • Tworek C; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Alberding D; Westat, Rockville, Maryland, USA.
  • Hull LC; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Cheng YC; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Maklan D; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Backinger CL; Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Compton WM; Westat, Rockville, Maryland, USA.
Tob Control ; 26(4): 371-378, 2017 07.
Article en En | MEDLINE | ID: mdl-27507901
ABSTRACT

BACKGROUND:

This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration's (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat.

METHODS:

The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study's design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use.

CONCLUSIONS:

The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA's regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation's burden of tobacco-related death and disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fumar / Salud Pública Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Tob Control Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fumar / Salud Pública Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Tob Control Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos